Shilpa Medicare Limited (SHILPAMED.BO)
INR 640.1
(5.03%)
INR 640.1
(5.03%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 11.51 Billion INR | 10.37% |
| 2022 | 10.43 Billion INR | -8.47% |
| 2021 | 11.4 Billion INR | 26.65% |
| 2020 | 9 Billion INR | 0.14% |
| 2019 | 8.98 Billion INR | 30.46% |
| 2018 | 6.88 Billion INR | -8.03% |
| 2017 | 7.49 Billion INR | 2.61% |
| 2016 | 7.3 Billion INR | 14.51% |
| 2015 | 6.37 Billion INR | 9.19% |
| 2014 | 5.83 Billion INR | 6.52% |
| 2013 | 5.48 Billion INR | 47.63% |
| 2012 | 3.71 Billion INR | 16.7% |
| 2011 | 3.18 Billion INR | 9.61% |
| 2010 | 2.9 Billion INR | 9.58% |
| 2009 | 2.64 Billion INR | 59.17% |
| 2008 | 1.66 Billion INR | 73.71% |
| 2007 | 958.12 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 2.92 Billion INR | 0.28% |
| 2023 Q1 | 2.6 Billion INR | 1.28% |
| 2023 Q3 | 2.86 Billion INR | -8.47% |
| 2023 FY | 11.51 Billion INR | 10.37% |
| 2023 Q4 | 2.91 Billion INR | 1.82% |
| 2023 Q2 | 3.12 Billion INR | 20.29% |
| 2022 Q2 | 2.62 Billion INR | 0.67% |
| 2022 Q4 | 2.56 Billion INR | -2.14% |
| 2022 FY | 10.43 Billion INR | -8.47% |
| 2022 Q1 | 2.61 Billion INR | -22.07% |
| 2022 Q3 | 2.62 Billion INR | -0.16% |
| 2021 FY | 11.4 Billion INR | 26.65% |
| 2021 Q2 | 2.95 Billion INR | 24.4% |
| 2021 Q1 | 2.37 Billion INR | 14.6% |
| 2021 Q3 | 2.72 Billion INR | -7.78% |
| 2021 Q4 | 3.35 Billion INR | 23.07% |
| 2020 Q3 | 1.91 Billion INR | -31.44% |
| 2020 FY | 9 Billion INR | 0.14% |
| 2020 Q1 | 2.22 Billion INR | 196.21% |
| 2020 Q2 | 2.78 Billion INR | 25.16% |
| 2020 Q4 | 2.07 Billion INR | 8.3% |
| 2019 Q4 | 752.39 Million INR | -68.23% |
| 2019 Q2 | 2.89 Billion INR | 80.08% |
| 2019 FY | 8.98 Billion INR | 30.46% |
| 2019 Q1 | 1.6 Billion INR | -3.94% |
| 2019 Q3 | 2.36 Billion INR | -18.3% |
| 2018 Q2 | 1.62 Billion INR | -18.11% |
| 2018 FY | 6.88 Billion INR | -8.03% |
| 2018 Q3 | 1.73 Billion INR | 6.87% |
| 2018 Q1 | 1.98 Billion INR | -15.48% |
| 2018 Q4 | 1.67 Billion INR | -3.36% |
| 2017 FY | 7.49 Billion INR | 2.61% |
| 2017 Q3 | 1.85 Billion INR | -9.05% |
| 2017 Q2 | 2.03 Billion INR | 22.99% |
| 2017 Q1 | 1.65 Billion INR | -25.15% |
| 2017 Q4 | 2.34 Billion INR | 26.38% |
| 2016 Q1 | 1.66 Billion INR | -15.38% |
| 2016 FY | 7.3 Billion INR | 14.51% |
| 2016 Q4 | 2.21 Billion INR | 21.8% |
| 2016 Q3 | 1.81 Billion INR | -13.23% |
| 2016 Q2 | 2.09 Billion INR | 26.27% |
| 2015 Q4 | 1.96 Billion INR | -1.23% |
| 2015 FY | 6.37 Billion INR | 9.19% |
| 2015 Q1 | 1.48 Billion INR | 8.54% |
| 2015 Q2 | 1.73 Billion INR | 16.57% |
| 2015 Q3 | 1.98 Billion INR | 14.77% |
| 2014 Q2 | 1.53 Billion INR | 10.63% |
| 2014 FY | 5.83 Billion INR | 6.52% |
| 2014 Q4 | 1.36 Billion INR | -11.44% |
| 2014 Q3 | 1.54 Billion INR | 0.55% |
| 2014 Q1 | 1.38 Billion INR | -3.7% |
| 2013 Q2 | 1.35 Billion INR | 19.53% |
| 2013 FY | 5.48 Billion INR | 47.63% |
| 2013 Q4 | 1.44 Billion INR | -6.54% |
| 2013 Q3 | 1.54 Billion INR | 13.57% |
| 2013 Q1 | 1.13 Billion INR | 15.4% |
| 2012 FY | 3.71 Billion INR | 16.7% |
| 2012 Q2 | 902.52 Million INR | 1.97% |
| 2012 Q3 | 940.4 Million INR | 4.2% |
| 2012 Q1 | 885.06 Million INR | -6.66% |
| 2012 Q4 | 985.24 Million INR | 4.77% |
| 2011 FY | 3.18 Billion INR | 9.61% |
| 2011 Q1 | 683.22 Million INR | 0.0% |
| 2011 Q4 | 948.26 Million INR | 13.17% |
| 2011 Q3 | 837.94 Million INR | 17.62% |
| 2011 Q2 | 712.38 Million INR | 4.27% |
| 2010 FY | 2.9 Billion INR | 9.58% |
| 2009 FY | 2.64 Billion INR | 59.17% |
| 2008 FY | 1.66 Billion INR | 73.71% |
| 2007 FY | 958.12 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 97.625% |
| NATCO Pharma Limited | 40.02 Billion INR | 71.224% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | -9.535% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -344.216% |
| Achyut Healthcare Limited | 61.36 Million INR | -18665.223% |
| Ajanta Pharma Limited | 42.08 Billion INR | 72.638% |
| Alkem Laboratories Limited | 126.67 Billion INR | 90.909% |
| Alpa Laboratories Limited | 1.08 Billion INR | -959.052% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 81.159% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 11.11% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 95.988% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -143.253% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | -49.511% |
| Brooks Laboratories Limited | 794.86 Million INR | -1348.811% |
| Divi's Laboratories Limited | 78.45 Billion INR | 85.321% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 95.875% |
| Eris Lifesciences Limited | 20.09 Billion INR | 42.682% |
| FDC Limited | 19.42 Billion INR | 40.729% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 90.251% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 49.562% |
| Granules India Limited | 45.06 Billion INR | 74.445% |
| Gufic Biosciences Limited | 8.06 Billion INR | -42.761% |
| Hester Biosciences Limited | 3.04 Billion INR | -278.138% |
| Indoco Remedies Limited | 17.89 Billion INR | 35.645% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 10.094% |
| Ipca Laboratories Limited | 76.22 Billion INR | 84.892% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -451.793% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -2183.952% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -1003.755% |
| Laurus Labs Limited | 50.01 Billion INR | 76.976% |
| Lupin Limited | 200.1 Billion INR | 94.245% |
| Mankind Pharma Limited | 103.34 Billion INR | 88.857% |
| Medicamen Biotech Limited | 1.79 Billion INR | -542.255% |
| Medico Remedies Limited | 1.44 Billion INR | -694.644% |
| Megasoft Limited | 373.95 Million INR | -2979.539% |
| Piramal Pharma Limited | 81.71 Billion INR | 85.906% |
| RPG Life Sciences Limited | 5.82 Billion INR | -97.853% |
| Sigachi Industries Limited | 3.98 Billion INR | -188.654% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -1424.387% |
| Unichem Laboratories Limited | 16.57 Billion INR | 30.518% |
| Wanbury Limited | 5.75 Billion INR | -100.053% |
| Windlas Biotech Limited | 6.3 Billion INR | -82.517% |
| ZIM Laboratories Limited | 3.67 Billion INR | -213.426% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 93.946% |
| Procter & Gamble Health Limited | 11.51 Billion INR | -0.03% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -173.39% |
| Bal Pharma Limited | 3.39 Billion INR | -239.486% |
| Strides Pharma Science Limited | 40.51 Billion INR | 71.573% |
| Venus Remedies Limited | 5.91 Billion INR | -94.709% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 36.568% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 31.619% |
| Aarti Drugs Limited | 25.28 Billion INR | 54.456% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 45.652% |
| Suven Life Sciences Limited | 116.92 Million INR | -9748.737% |
| Ind-Swift Limited | 5.02 Billion INR | -129.189% |
| Valiant Laboratories Limited | 1.82 Billion INR | -532.55% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 66.948% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 7.008% |
| Themis Medicare Limited | 3.81 Billion INR | -201.656% |
| Hikal Limited | 17.84 Billion INR | 35.47% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 89.141% |
| Sequent Scientific Limited | 13.69 Billion INR | 15.925% |
| Novartis India Limited | 3.35 Billion INR | -243.69% |
| Wockhardt Limited | 27.89 Billion INR | 58.709% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 82.819% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -2776.469% |
| Neuland Laboratories Limited | 15.58 Billion INR | 26.112% |
| Morepen Laboratories Limited | 17.01 Billion INR | 32.334% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -645.99% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | -212.431% |